Prestige BioPharma Limited (950210.KS)
KRW 15050.0
(-4.57%)
KRW 15050.0
(-4.57%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -31.04 Billion KRW | -252.54% |
| 2022 | 10.51 Billion KRW | 148.9% |
| 2021 | -206.9 Billion KRW | -146.99% |
| 2020 | -5.68 Billion KRW | -193.76% |
| 2019 | -13.71 Billion KRW | -84.53% |
| 2018 | -686.46 Million KRW | -27.89% |
| 2017 | -1.98 Billion KRW | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 Q2 | -15.18 Billion KRW | -0.83% |
| 2023 Q3 | -12.37 Billion KRW | 18.46% |
| 2023 Q4 | 5.75 Billion KRW | 146.47% |
| 2023 Q1 | -15.05 Billion KRW | -131.67% |
| 2022 Q1 | -12.35 Billion KRW | 93.26% |
| 2022 Q4 | 47.54 Billion KRW | 341.01% |
| 2022 FY | - KRW | 148.9% |
| 2022 Q2 | -17.03 Billion KRW | -37.8% |
| 2022 Q3 | -19.72 Billion KRW | -15.83% |
| 2021 Q1 | -5.3 Billion KRW | 55.36% |
| 2021 Q4 | -183.36 Billion KRW | -1313.97% |
| 2021 Q3 | -12.96 Billion KRW | -47.4% |
| 2021 Q2 | -8.79 Billion KRW | -65.76% |
| 2021 FY | - KRW | -146.99% |
| 2020 Q3 | -9.8 Billion KRW | -237.87% |
| 2020 Q1 | -2.49 Billion KRW | -1.04% |
| 2020 FY | - KRW | -193.76% |
| 2020 Q2 | -2.9 Billion KRW | -16.45% |
| 2020 Q4 | -11.88 Billion KRW | -21.31% |
| 2019 FY | - KRW | -84.53% |
| 2019 Q3 | -2.43 Billion KRW | 0.0% |
| 2019 Q4 | -2.46 Billion KRW | -1.11% |
| 2018 FY | - KRW | -27.89% |
| 2017 FY | - KRW | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| ORIENT BIO Inc. | 15.66 Billion KRW | 298.171% |
| Green Cross Holdings Corporation | 66.84 Billion KRW | 146.45% |
| Green Cross Holdings Corporation | 109.81 Billion KRW | 128.274% |
| Pharmicell Co., Ltd. | 8.44 Billion KRW | 467.847% |
| Green Cross Corporation | 109.81 Billion KRW | 128.274% |
| GeneOne Life Science, Inc. | -63.69 Billion KRW | 51.259% |
| Celltrion, Inc. | 897.26 Billion KRW | 103.46% |
| Samsung Biologics Co.,Ltd. | 1603.46 Billion KRW | 101.936% |
| SK bioscience Co.,Ltd. | 22.77 Billion KRW | 236.311% |
| SK Biopharmaceuticals Co., Ltd. | -22.2 Billion KRW | -39.824% |